课题基金 / 基金详情

IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS

IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
IDEC Y2B8 与 RITUXAN 在难治性低级别或滤泡 B 细胞非霍奇金淋巴瘤中的比较
批准号：
6263459
负责人：
MANSOOR N SALEH
金额：
$2.95万
依托单位：
UNIVERSITY OF ALABAMA AT BIRMINGHAM
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6263459
关键词：
antibody antineoplastics clinical research human subject human therapy evaluation neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy neoplasm /cancer relapse /recurrence nonHodgkin's lymphoma radiotracer

项目摘要

项目成果

MANSOOR N SALEH的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a pivotal, randomized phase III clinical trial comparing the radiolabeled Y2B8 with the unlabeled C2B8 antibody in relapsed or refractory low-grade lymphoma. The unlabeled agent has a reponse rate of 30% with approximately 5% complete remissions in phase II settings as compared to 70% and 40%, respectively, for the phase II study of Y2B8. The current pivotal multi-institutional trial will address the issue of the superiority of one or the other reagent. It should be noted that there is a cross-over arm whereby patients receiving the unlabeled antibody can receive the radiolabeled antibody.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
IDEC Y2B8 VS RITUXAN IN REFRACTORY LOW GRADE OR FOLLICULAR B CELL NON HODGKINS
ANTI C20 IDEC C2B8 (RITUXIMAB) IN AIDS ASSOCIATED NON HODGKINS LYMPHOMA
海外基金